Pharmaceutical supply chains are increasingly vulnerable to climate-related disruptions like hurricanes, floods, and heatwaves, which threaten the availability of life-saving medications. This article outlines a five-step framework to help companies prepare for and recover from these challenges. Key actions include assessing climate risks, strengthening supplier relationships, refining inventory management, upgrading infrastructure, and implementing continuous monitoring. By addressing these risks now, companies can reduce shortages, avoid costly delays, and ensure patient care remains uninterrupted.

Key Takeaways:

• Risk Assessment: Identify and map climate hazards across supply chain locations.

• Supplier Resilience: Evaluate supplier vulnerabilities and integrate climate measures into contracts.

• Inventory Management: Stockpile critical drugs and develop surge capacity protocols.

• Infrastructure Upgrades: Fortify facilities against climate risks and secure IT systems.

• Continuous Monitoring: Track key performance metrics, report transparently, and refine strategies.

This proactive approach ensures supply chains remain stable during extreme weather events, safeguarding both operations and patient health.

Navigating Drug Shortages: Climate Resilience and Operational Innovation in Pharmacy

Step 1: Conduct a Complete Climate Risk Assessment

Building a climate-resilient pharmaceutical supply chain starts with identifying your specific climate threats and vulnerabilities. This should be a continuous process, adapting to the changing risks posed by climate shifts. Begin by mapping regional hazards, then assess how these risks affect your supply chain and its infrastructure.

Identify Climate Hazards

Climate threats vary significantly across the United States. Hurricanes pose a risk to facilities in the Southeast and Gulf Coast, flooding is a concern for the Midwest and Mississippi River basin, wildfires threaten the West Coast, and heat waves impact the entire country, particularly the South and Southwest [1][3].

A stark example of such risks is Hurricane Helene, which disrupted IV saline supply chains, causing shortages across the nation [2]. Despite the predictability of events like hurricanes, many companies in high-risk areas remain unprepared for their impact.

To create a detailed hazard profile, pharmaceutical companies can leverage resources like NOAA data, FEMA flood maps, and local government reports. GIS mapping tools are invaluable for visualizing risks across supply chain locations, helping pinpoint areas of highest exposure [1]. Partnering with experts, such as Council Fire, can provide tailored scenario analysis and strategic insights to enhance hazard assessments.

This regional hazard mapping is especially critical given that over 80% of active pharmaceutical ingredients (APIs) for essential medicines are sourced internationally. This reliance increases vulnerability to climate disruptions both domestically and abroad [2]. Companies must evaluate risks not only to their own facilities but also to international suppliers and shipping routes.

Evaluate Supply Chain Vulnerabilities

Once climate hazards are identified, the next step is assessing how these threats could disrupt critical points in the supply chain. This involves conducting site-specific risk evaluations for manufacturing facilities, warehouses, distribution centers, and delivery points [2][3].

Manufacturing facilities are particularly vulnerable as single points of failure. For example, those located in flood-prone areas may need elevated storage and backup power systems. Warehouses storing temperature-sensitive drugs require redundant cooling systems and emergency generators. Distribution routes also face challenges, as floods, wildfires, or extreme heat can block transportation paths or damage medications during transit [2][3].

The assessment should also cover factors like building codes, emergency power systems, and distribution route redundancy. Facilities relying on a single transportation corridor are at high risk if that route becomes unusable. Forward-thinking companies establish multiple transportation pathways and maintain relationships with alternative logistics providers.

Between 2016 and 2022, drug shortages in the U.S. rose by 30%, with climate events cited as a contributing factor [2]. This highlights the need for comprehensive vulnerability assessments that consider not just obvious risks but also less apparent dependencies that could lead to significant disruptions.

Map Dependencies on Key Infrastructure

After identifying hazards and vulnerabilities, it’s essential to map out the supply chain’s reliance on external infrastructure. Pharmaceutical operations depend on a complex network of external systems, such as energy, water, transportation, and IT. Disruptions to any of these can ripple through the supply chain, making it crucial to inventory these dependencies and understand their potential impact [5].

• Energy: Reliable power is critical for manufacturing, cold storage, and quality control systems. Companies should evaluate local utility resilience, map energy sources, and ensure backup capacity, including adequate fuel supplies for extended outages.

• Water: Manufacturing often requires large volumes of clean water. Assessing the reliability of municipal water sources, identifying alternative supplies, and maintaining on-site storage capacity are essential steps.

• Transportation: Highways, railways, ports, and airports connect facilities to suppliers and customers. Identifying alternative routes and working with multiple providers can help mitigate disruptions.

• IT Systems: These systems are vital for managing orders, inventory, and communications. Evaluating data center locations, exploring cloud-based solutions, and establishing robust backups can ensure operational continuity.

The Federal Emergency Management Agency (FEMA) reports that over 40% of businesses never reopen after a major disaster [1]. Understanding these interdependencies allows pharmaceutical companies to build redundancies and strengthen their operations before disaster strikes.

Taking a systematic approach to climate risk assessment, including identifying hazards, evaluating vulnerabilities, and mapping infrastructure dependencies, sets the stage for a more resilient supply chain. This ensures pharmaceutical companies can make informed decisions about where to invest in redundancies and prioritize resilience strategies effectively.

Step 2: Strengthen Supplier Partnerships for Resilience

Once you've completed a climate risk assessment, the next logical step is to focus on strengthening partnerships with your suppliers. This is especially critical in the pharmaceutical sector, where many active pharmaceutical ingredients and essential components are sourced externally. Building these partnerships ensures that resilience strategies are not limited to internal operations but extend across the entire supply network.

Supplier Risk Mapping and Prioritization

Understanding supplier vulnerabilities is key to prioritizing resilience efforts. Begin by identifying suppliers that are crucial to maintaining product availability, particularly those providing key medicines or single-source components that could lead to shortages if disrupted.

A geographic risk assessment is a good starting point. Evaluate each supplier's location using climate hazard maps, paying attention to risks like hurricanes, floods, wildfires, and extreme heat. Suppliers in high-risk areas - such as hurricane zones or flood-prone regions - should be flagged for immediate attention.

Next, assess the physical resilience of each supplier's facilities. Look into factors like backup power systems and transportation access. Facilities without climate adaptations or those dependent on a single transportation route are inherently riskier.

Gather detailed data on each supplier's history with climate events, including their recovery times and the effectiveness of their business continuity plans. This information will help you rank suppliers by their vulnerability and the potential impact of disruptions.

Include Climate Adaptation in Procurement

Using the insights from supplier risk mapping, integrate climate adaptation requirements into procurement contracts. By embedding resilience measures as contractual obligations, you can ensure that suppliers take meaningful steps to address climate risks throughout the supply chain.

Contracts should stipulate that suppliers maintain updated climate risk assessments, implement necessary adaptation measures (like flood-proofing or installing backup power systems), and provide regular progress reports. Procurement policies can also prioritize suppliers with strong environmental practices or recognized certifications. When evaluating bids, consider not just cost and quality but also a supplier's preparedness and track record in handling past disruptions.

Environmental, Social, and Governance (ESG) considerations are increasingly shaping procurement strategies. Comprehensive ESG policies should extend to all supplier agreements, making climate adaptation a core element of vendor selection. Regular audits - conducted annually or after major climate events - help ensure compliance and highlight emerging risks. Performance dashboards can also be useful for monitoring key metrics such as recovery times and overall adherence to resilience standards.

Promote Local and Regional Sourcing

Another effective way to enhance supply chain resilience is by reducing reliance on distant suppliers. Local and regional sourcing minimizes transportation risks and allows for quicker adjustments when disruptions occur.

Strategic sourcing involves identifying critical products that can be procured from domestic or nearby regions. Focus on essential medicines and components, and work to establish relationships with qualified local suppliers. The benefits of local sourcing were evident during the COVID-19 pandemic when shorter supply chains proved to be more adaptable [2].

To further support local suppliers, consider implementing supplier development programs. These programs can provide technical assistance and training, helping regional suppliers meet strict quality and regulatory standards. This not only creates strong backup options but also contributes to local economic growth.

Maintaining relationships with multiple suppliers - both local and distant - is another way to build flexibility. Clear contingency plans should outline how to switch suppliers and adjust procurement volumes in response to climate events.

Organizations like Council Fire can assist in developing local sourcing networks by facilitating collaboration and providing strategic guidance. Their expertise can help pharmaceutical companies balance resilience objectives with regulatory requirements and cost considerations [1].

Step 3: Inventory Management and Emergency Preparedness

Once supplier partnerships are solidified, the next step is refining inventory management and emergency protocols. This ensures access to critical medications even during climate-related disruptions. Effective strategies include stockpiling essential drugs, implementing surge protocols, and crafting robust business continuity plans.

Stockpile Critical Pharmaceuticals

A focused approach to stockpiling is essential, prioritizing life-saving and high-risk medications based on clinical importance and historical disruption trends. Federal guidelines and critical medicines lists can help identify these priority products. For instance, Hurricane Helene's impact on intravenous (IV) saline supplies highlighted how climate events can jeopardize access to fundamental medical resources [2].

Efforts to prioritize active pharmaceutical ingredients (APIs) for domestic production align with these preparedness goals, supported by expert panels and federal recommendations. Medications like antibiotics, IV fluids, and insulin are often flagged as essential for stockpiling. Using historical demand patterns and lead times, companies can determine optimal stock levels while accounting for surge demand during emergencies and shelf-life limitations [2].

Advanced inventory systems powered by AI and big data analytics play a vital role here. These systems can predict shortages, automate reordering, and minimize waste by tracking expiration dates. Real-time monitoring ensures stock rotation, reducing losses, while collaboration with suppliers and public health agencies enhances forecasting accuracy [2][3].

Develop Surge Capacity Protocols

To prepare for sudden spikes in demand, surge capacity protocols are critical. The COVID-19 pandemic underscored the importance of having flexible manufacturing and distribution agreements ready to handle emergencies [2].

These protocols should include pre-negotiated contracts, scalable logistics, and flexible staffing arrangements. Contracts must outline contingency measures for priority service during crises and establish clear triggers for activation [2]. Regular simulation exercises and drills help test system responsiveness, staff readiness, and communication pathways. Building redundancy in transportation and warehousing is equally important to avoid single points of failure [2][5].

Supply chain agility - being able to quickly adapt production, sourcing, or distribution - becomes a key asset during climate emergencies. Developing substitution capacities for alternative, functionally similar products ensures continuity when primary options are unavailable [2].

Create Business Continuity Plans

Business continuity plans act as a roadmap for maintaining pharmaceutical supply chains during disruptions. These plans should include backup transportation routes, digital communication systems, and protocols for rapid regulatory compliance. Real-time monitoring systems can enable swift rerouting during crises, while cloud-based platforms provide visibility across the supply chain to support quick decision-making.

Emergency communication tools are indispensable for coordinating responses, and plans should include procedures for emergency use authorizations and cybersecurity measures [1][2][5]. Supplier and distributor redundancy is another critical element, ensuring that a single failure does not paralyze the entire supply chain. Early warning systems can help identify potential issues before they escalate [2][5].

Testing and updating these plans regularly through drills and scenario planning is essential. Companies should also evaluate the resilience of supporting infrastructure - such as energy, transportation, and telecommunications - on both local and national levels [5]. Healthcare facilities, in particular, must ensure access to safe water for cooling systems, diagnostic equipment, and medical treatments [3].

Organizations like Council Fire offer guidance on integrating sustainability into continuity planning. By embedding sustainability into these strategies, businesses can enhance resilience and drive innovation, addressing both immediate climate risks and long-term supply chain stability [4].

Step 4: Build Resilient Infrastructure and Technology Systems

With the groundwork laid through risk assessments and supplier resilience measures, the next step is to strengthen both physical and digital infrastructure. Climate-related disruptions - like flooding, hurricanes, extreme heat, and wildfires - pose serious risks to the systems that ensure a steady supply of medications to patients [1][2]. Addressing these challenges requires a comprehensive approach that focuses on both physical hardening and digital security.

Facility Hardening and Energy Resilience

The resilience of physical infrastructure underpins the stability of the supply chain. Natural disasters such as hurricanes, floods, and wildfires can severely impact pharmaceutical facilities. To mitigate these risks, companies need to tailor hardening measures to the specific vulnerabilities of each location.

For facilities in hurricane-prone areas, wind-resistant construction and backup generators are essential. In flood zones, elevating critical equipment and installing sump pumps can prevent damage. Temperature-controlled storage areas, crucial for maintaining FDA-compliant conditions, demand particular attention. Backup generators capable of powering refrigeration units and essential IT systems ensure pharmaceutical products remain safe during extended power outages [1][3].

Energy resilience isn’t just about having backup power during emergencies. Uninterruptible power supplies (UPS) protect sensitive equipment from power surges, while upgraded HVAC systems maintain stable temperature and humidity levels [1][3]. Many facilities are also turning to renewable energy sources like solar panels and exploring microgrids to reduce reliance on traditional power grids and enhance energy independence.

The importance of these measures is clear from past events. After Hurricane Maria struck Puerto Rico, pharmaceutical plants that had invested in redundant generators, elevated storage, and robust IT backups were able to recover operations more quickly during subsequent storms [2]. Similarly, a Midwest facility that implemented flood-proofing and solar power backups maintained uninterrupted cold chain storage during a regional power outage, highlighting the value of proactive investments [1].

Secure IT Systems and Data Resilience

While physical resilience is critical, ensuring the security and reliability of digital systems is equally important. Strong IT systems provide essential supply chain visibility during emergencies. One key strategy is maintaining redundant data centers in geographically diverse locations, which ensures operations can continue if a primary facility is compromised [1][2].

Cloud-based platforms add another layer of resilience, offering scalable backup capacity and reducing dependency on any single physical location. However, on-site systems still require protection. Measures such as surge protectors, climate-controlled server rooms, and elevated installations help safeguard sensitive electronics from environmental threats [1].

Cybersecurity becomes even more crucial during climate-related emergencies, when normal protocols may be disrupted. Multi-factor authentication, regular vulnerability assessments, and tailored incident response plans protect data integrity during such times [2]. Regular backups ensure critical information remains accessible even if systems fail.

Key metrics for evaluating IT resilience include system uptime, the success rate of data backups, and recovery times after disruptions [2][3]. Monitoring these indicators not only supports continuous improvement but also helps justify ongoing investments in resilience infrastructure. Compliance with FDA regulations for drug storage, USP standards for medicines, and cybersecurity requirements is also vital [2]. Routine audits verify that both physical and digital systems can perform under stress.

Regular Infrastructure Audits

To maintain resilience, infrastructure must be regularly assessed and improved. Annual inspections of facilities, backup systems, and IT performance are essential [3][6]. These audits should involve multidisciplinary teams, including facility managers, IT specialists, and supply chain experts, and use standardized checklists to ensure thorough evaluations [7].

Performance indicators such as the frequency and duration of power outages, temperature fluctuations in storage areas, and the reliability of emergency systems should be tracked during audits [2][3]. Documenting findings and creating actionable plans to address weaknesses ensures that audits lead to meaningful improvements.

Emergency drills can also uncover vulnerabilities that routine operations might overlook. For example, backup generators should be tested under real-world conditions, and IT failover systems should be periodically activated to confirm their functionality.

Collaboration with experts and external partners further strengthens resilience. Organizations like Council Fire can provide strategic guidance on integrating climate resilience into infrastructure planning. Partnerships with local utilities, emergency services, technology providers, and consultants can enhance both planning and response capabilities [1][2]. These relationships offer access to shared resources, such as backup power during extended outages, and enable faster repairs when systems fail.

Continuous improvement is key. Annual reviews, scenario planning, and updates to emergency protocols ensure infrastructure remains robust against evolving climate risks. Feedback loops from audits and incident reports should inform future investments, enabling organizations to adapt and stay ahead of emerging challenges [2][7]. By staying informed about new technologies and shifting climate patterns, companies can ensure their infrastructure remains resilient for years to come.

Step 5: Monitor, Report, and Improve Continuously

Once infrastructure is fortified, the next step is to maintain a vigilant approach through ongoing monitoring and improvement. Climate risks are not static, and pharmaceutical supply chains must remain agile to ensure resilience efforts stay effective in the face of evolving challenges.

Define Key Metrics and KPIs

Identifying and tracking meaningful metrics is vital for translating climate resilience into actionable data. For instance, supply chain downtime serves as a critical indicator of operational resilience. Similarly, incident response times, measured in minutes or hours, reflect how quickly resources can be mobilized during emergencies. Monitoring cost impacts, expressed in U.S. dollars, helps quantify the financial benefits of adaptation measures [2].

Other valuable metrics include inventory levels of essential pharmaceuticals and the frequency of climate-related disruptions. Consistent measurement standards across the U.S. allow for reliable year-over-year comparisons. For example, tracking the number of days a critical drug is unavailable during a climate event provides actionable insights that directly affect patient care [2].

Advanced supply chain management systems streamline data collection and improve accuracy. Dashboards that consolidate incident reports, inventory levels, and supplier performance offer a clear overview, while automated alerts for threshold breaches - such as low inventory - enable timely intervention to prevent shortages [1] [2].

Focusing on metrics that directly impact business continuity and patient safety is essential. Monitoring should target the most vulnerable points identified during risk assessments, with annual reviews ensuring metrics remain relevant as risks and operations evolve. These efforts lay the foundation for transparent communication with stakeholders and informed scenario planning.

Engage Stakeholders and Report Transparently

Engaging stakeholders effectively fosters collaboration across teams, sectors, and communities to develop practical solutions. Regular meetings, open communication about progress and challenges, and collaborative scenario planning exercises build trust and encourage collective action [1].

"Council Fire is helping us lay the foundation for what we believe is one of the most innovative local climate resilience planning models in the country. Whether it’s strategy development, financing mechanisms, impact metrics, decision-making tools, or storytelling, their guidance is instrumental in shaping our approach, implementing projects, and building trust with stakeholders."

• Matthew Fleming, Executive Director, Resilience Authority of Annapolis and Anne Arundel County[4]

Council Fire's expertise enhances communication strategies with regulators, suppliers, and customers. Their guidance ensures that reports align with regulatory standards and industry expectations, reinforcing stakeholder confidence [1].

Transparent climate resilience reports should include key metrics and KPIs, summaries of incidents, actions taken, lessons learned, and progress toward adaptation goals. These reports should also detail stakeholder engagement efforts and plans for future improvements. Updates should be provided at least annually, with interim reports following significant climate events or major risk changes [1] [2].

Turning complex climate adaptation efforts into engaging narratives helps build trust with executives, investors, and regulators, maintaining momentum for continued investment in resilience strategies.

Annual Review and Scenario Planning

Annual reviews, grounded in defined metrics and transparent reporting, are key to refining resilience strategies. These reviews should incorporate scenario planning exercises that explore various climate risk scenarios - such as extreme heatwaves, hurricanes, or supply chain disruptions. This process identifies vulnerabilities and informs investments like diversifying suppliers or increasing buffer stock [2].

Regular reviews also help detect trends that guide adaptive strategies. For example, companies with robust monitoring systems and diversified supplier networks recover more quickly than those dependent on single-source suppliers [2].

Organizations that conduct annual climate scenario planning report 35% better operational continuity during extreme weather events compared to those that don’t [2]. Additionally, a 2023 Healthcare Supply Chain Association survey found that 78% of healthcare organizations with strong climate resilience monitoring systems experienced fewer supply chain disruptions over the past year [2].

Addressing challenges like data silos and inconsistent standards requires investment in integrated data systems and standardized measurement frameworks. Partnering with third-party experts can also ensure reports meet stakeholder expectations and regulatory requirements [1] [2].

Embedding continuous improvement into the organizational culture calls for strong leadership, regular training, clear accountability, and incentives for proactive risk management. Feedback loops ensure that lessons from incidents and annual reviews lead to updates in policies and processes, keeping climate resilience a dynamic priority across the organization [1]. Recognizing employee contributions to these efforts further strengthens this culture and promotes sustained vigilance.

Regular updates to emergency protocols, guided by annual reviews and incident feedback, ensure that response capabilities keep pace with changing climate conditions. This adaptive approach enables pharmaceutical companies to stay ahead of emerging risks while maintaining the supply chain stability that patients rely on.

Conclusion: A Pathway to Climate-Ready Pharma Supply Chains

Creating pharma supply chains that can withstand climate challenges requires a major shift in how risks are managed and how success is defined. The five-step framework discussed earlier provides a clear guide, moving from reactive crisis management to proactive resilience planning.

The pharmaceutical industry is facing mounting pressures. In 2023, drug shortages hit a five-year high, with over 300 medications in limited supply - many due to supply chain disruptions worsened by extreme weather events [2]. These numbers highlight the urgency for well-rounded climate adaptation strategies.

Taking proactive steps is key to building resilient supply chains. This means conducting detailed climate risk assessments, diversifying supplier networks, and investing in infrastructure designed to endure disruptions. Adopting this forward-thinking approach requires reimagining traditional business practices and making sustainability a core driver of innovation and growth. Such efforts lay the groundwork for unified action among all stakeholders.

Collaboration plays a pivotal role in achieving resilience. No pharmaceutical company can tackle this challenge alone. Partnerships with suppliers, industry groups, and specialized organizations are essential to fostering shared understanding and driving collective solutions. Council Fire emphasizes the importance of bringing together diverse groups - across industries, communities, and teams - to co-create practical, lasting solutions [4].

"Sustainability isn't a side gig - it's a growth strategy. We help organizations embed sustainability as a driver of innovation, resilience, and long-term success. That starts with deeply understanding your goals, challenges, and vision for impact."

• Council Fire [4]

Beyond proactive measures, aligning financial goals with environmental and social impacts marks a transformative shift for the pharmaceutical sector. Companies that embrace climate resilience often find that these investments yield both risk reduction and economic benefits. For example, energy efficiency upgrades, waste reduction programs, and local sourcing efforts not only stabilize supply chains but also cut long-term operational costs.

Expert insight can accelerate these efforts. Organizations like Council Fire offer strategic planning, frameworks for collaboration, and communication tools to help pharmaceutical companies navigate the complexities of climate adaptation. Their expertise in sustainable business practices and resource management helps businesses align resilience strategies with broader operational goals [1] [5].

Adapting to climate risks is an ongoing journey. As these risks evolve, supply chains must stay flexible and responsive. Companies that embed resilience into their culture - through regular training, clear accountability, and incentive programs - are better equipped to thrive over the long term.

The urgency to act cannot be overstated. Recent disruptions caused by hurricanes and extreme weather have exposed critical weaknesses in medical supply chains. Taking steps now not only strengthens the delivery of life-saving medications but also provides a competitive edge. Investments in climate resilience go beyond managing risks - they offer a strategic opportunity to create lasting value for businesses, communities, and stakeholders alike.

FAQs

What steps can pharmaceutical companies take to assess and address climate risks in their supply chains?

Pharmaceutical companies can tackle climate risks in their supply chains by adopting a clear and methodical strategy:

• Evaluate risks: Start by pinpointing weak spots in the supply chain. This involves analyzing factors like extreme weather patterns, resource limitations, and changes in regulations. Rank these risks based on their likelihood and potential impact.

• Collaborate with stakeholders: Work closely with suppliers, distributors, and other critical partners. Sharing data and insights can lead to more aligned and effective strategies for addressing vulnerabilities.

• Boost resilience: Enhance the robustness of the supply chain by diversifying supplier networks, refining transportation routes, and adopting sustainable practices. This might include investing in energy-efficient infrastructure or renewable energy solutions.

Taking these steps not only protects business operations but also supports broader environmental and social objectives.

How can pharmaceutical companies build stronger supplier partnerships to mitigate climate-related risks?

To create stronger supplier relationships and tackle risks tied to climate change, pharmaceutical companies can take a series of thoughtful actions. Begin with a thorough risk assessment to pinpoint weaknesses in the supply chain, such as areas vulnerable to extreme weather events or potential resource scarcities. Work closely with suppliers to craft contingency plans that safeguard operations against climate-related disruptions.

Encourage open dialogue by sharing your climate resilience goals and motivating suppliers to embrace sustainable practices. Supporting suppliers through training programs can also help them align with your company's environmental objectives. Another practical step is diversifying your supplier network to avoid over-reliance on any single provider, ensuring greater adaptability in times of crisis. By implementing these strategies, companies can build stronger partnerships and a supply chain better prepared for climate challenges.

Why are continuous monitoring and transparent reporting essential for creating a climate-resilient pharmaceutical supply chain?

Continuous monitoring and open reporting play a crucial role in creating a pharmaceutical supply chain that can withstand the challenges posed by climate change. These practices allow companies to pinpoint risks, track progress, and make smarter, data-driven decisions. By keeping tabs on essential metrics like greenhouse gas emissions, energy consumption, and supply chain disruptions, businesses can tackle weaknesses head-on and adjust to evolving conditions more effectively.

Transparent reporting builds trust among key stakeholders - regulators, investors, and customers - by showcasing a genuine commitment to accountability and environmental responsibility. It also promotes collaboration throughout the supply chain, aligning all partners toward common climate resilience objectives. Together, these efforts help pharmaceutical companies maintain their competitive edge while minimizing their environmental footprint.

Related Blog Posts

• How to Manage Supply Chain Risks in Impact Portfolios

• 5 Steps to Decarbonize Pharma Manufacturing

• How to Build a Climate Resilience Plan for Corporations

• How to Build a Climate Resilience Plan for Maritime & Logistics Companies